EA201990253A1 - Гуманизированные антитела против s100a9 и их применение - Google Patents

Гуманизированные антитела против s100a9 и их применение

Info

Publication number
EA201990253A1
EA201990253A1 EA201990253A EA201990253A EA201990253A1 EA 201990253 A1 EA201990253 A1 EA 201990253A1 EA 201990253 A EA201990253 A EA 201990253A EA 201990253 A EA201990253 A EA 201990253A EA 201990253 A1 EA201990253 A1 EA 201990253A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
antibodies against
humanized antibodies
toll
receptor
Prior art date
Application number
EA201990253A
Other languages
English (en)
Inventor
Филипп Тессье
Мелани Тардиф
Траян Сулеа
Original Assignee
Юниверсите Лаваль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Лаваль filed Critical Юниверсите Лаваль
Publication of EA201990253A1 publication Critical patent/EA201990253A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предлагается ингибитор Toll-подобного рецептора 2 (TLR2), специфично блокирующий взаимодействие между белком S1009А и Toll-подобным рецептором 2, а конкретнее - гуманизированное антитело против белка S1009А для подавления и лечения воспалительных состояний у людей. В частности, это гуманизированное антитело специфично блокирует взаимодействие между белком S1009А и Toll-подобным рецептором 2.
EA201990253A 2015-07-13 2016-07-11 Гуманизированные антитела против s100a9 и их применение EA201990253A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562191733P 2015-07-13 2015-07-13
PCT/CA2016/050810 WO2017008153A1 (en) 2015-07-13 2016-07-11 Humanized anti-s100a9 antibody and uses thereof

Publications (1)

Publication Number Publication Date
EA201990253A1 true EA201990253A1 (ru) 2019-06-28

Family

ID=57756600

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990253A EA201990253A1 (ru) 2015-07-13 2016-07-11 Гуманизированные антитела против s100a9 и их применение

Country Status (11)

Country Link
US (1) US11359010B2 (ru)
EP (1) EP3481863A4 (ru)
JP (1) JP6953033B2 (ru)
KR (1) KR102234279B1 (ru)
CN (1) CN109641951A (ru)
AU (1) AU2016293391B2 (ru)
BR (1) BR112019000635A2 (ru)
CA (1) CA3030320A1 (ru)
EA (1) EA201990253A1 (ru)
MX (1) MX2019000429A (ru)
WO (1) WO2017008153A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019010566A1 (en) * 2017-07-10 2019-01-17 UNIVERSITé LAVAL ANTI-S100A8 / A9 TO INHIBIT THE IMMUNOSUPPRESSIVE ACTIVITY OF MDSC CELLS
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023000903A (es) 2020-07-23 2023-04-20 Univ Erasmus Med Ct Rotterdam Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas.
CN114057860B (zh) * 2021-11-09 2023-10-20 中国科学技术大学 特定组氨酸甲基化修饰的s100a9蛋白免疫原、多克隆抗体及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1519749B1 (en) * 2002-07-05 2009-04-08 Universite Laval Chemotactic factor inhibitor for inhibiting inflammatory reactions
WO2005028509A1 (en) * 2003-09-23 2005-03-31 Technische Universitaet Muenchen Tlr2 antagonistic antibody and use thereof
WO2008131908A1 (en) * 2007-04-26 2008-11-06 Active Biotech Ab S100a9 interaction screening method
US8420387B2 (en) * 2009-11-06 2013-04-16 Agrivida, Inc. Intein-modified enzymes, their production and industrial applications

Also Published As

Publication number Publication date
EP3481863A4 (en) 2020-03-11
JP2019527212A (ja) 2019-09-26
WO2017008153A1 (en) 2017-01-19
AU2016293391A1 (en) 2019-02-14
JP6953033B2 (ja) 2021-10-27
AU2016293391B2 (en) 2023-11-23
MX2019000429A (es) 2019-06-10
EP3481863A1 (en) 2019-05-15
CA3030320A1 (en) 2017-01-19
KR102234279B1 (ko) 2021-03-30
BR112019000635A2 (pt) 2019-04-30
US11359010B2 (en) 2022-06-14
KR20190032419A (ko) 2019-03-27
US20210277101A1 (en) 2021-09-09
CN109641951A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
CR20180225A (es) Anticuerpo anti-tigit y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201890468A1 (ru) Новые антитела против белка pd-1
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
CR20170026A (es) Anticuerpos anti-tau humanizados
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
CO2019008786A2 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
EA201992460A1 (ru) Антитела-агонисты btla и их применение
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
EA201890739A1 (ru) Анти-s100a8 для лечения лейкемии